Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
用户EO9nReo4Hj6s
1个月前
39
10
已完结
1. 系统已在2025-11-11 14:22:48对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s0140-6736(25)01720-9
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673625017209
其他信息:
出版社: Elsevier BV
作者: Zheng Wang; Jia Fan; Shaolai Zhou; Yunfan Sun; Fei Liang; Yuan Ji; Fangming Gu; Tao Li; Li Peng; Tao Peng; Xiaolun Huang; Zhenbin Ding; Dousheng Bai; Bangde Xiang; Guang Tan; Tianfu Wen; Yongyi Zeng; Feng Han; Yu Zhang; Shengdong Wu; Haitao Zhao; Yi Chen; Guoming Shi; Zhiguo Hou; Ying Sun; Wenqing Zhu; Jian Zhou
